Regorafenib: A Review in Hepatocellular Carcinoma
In conclusion, current evidence suggests that regorafenib is an important new targeted therapy option for the treatment of HCC patients who have progressed on sorafenib therapy.
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Cancer & Oncology | Carcinoma | Diarrhoea | Drugs & Pharmacology | Hepatocellular Carcinoma | Hypertension | Liver Cancer | Skin